Cancers MDPI

📢 Cancers MDPI was awarded an updated Impact Factor of 4.5 in the 2023 Journal Citation Reports released by Clarivate in June 2024. The journal rank has now been upgraded to JCR Q1 (78/322 in the 'Oncology' category, 5-Year Impact Factor: 4.9). 👉 Read more: https://lnkd.in/g7JUNySw

💬Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies, with continuously increasing cases and fatalities. Today we share the highly cited papers on the topic of HCC✅ Read more publications about HCC at➡ https://lnkd.in/d4M5y5q9

📑Today we share the #Article "Clinical Implications of Circulating Tumor Cells in Patients with Esophageal Squamous Cell Carcinoma: Cancer-Draining Blood Versus Peripheral Blood" 👥by Dong Chan Joo et al. Pusan National University Access the full paper here⏩ https://lnkd.in/d8nZtxhB 🔹1. What are the main findings?  CTCs and TWIST-positive CTCs were found at higher concentrations in the azygos vein (a cancer-draining vein) than in the peripheral vein. This suggests that cancer-draining veins may provide more accurate information regarding tumor activity.  There was no significant correlation between CTC levels and clinicopathological factors such as tumor size, stage, or histological differentiation, indicating that CTC counts alone may not fully reflect the clinical profile of a tumor.  Although CTCs were more abundant in the azygos vein, their predictive value for chemotherapy response or prognosis requires further investigation in larger studies. 🔹2. What are the implications of the main findings?  The presence of more CTCs in cancer-draining veins implies that they could be valuable biomarkers for predicting outcomes and guiding treatment strategies for esophageal squamous cell carcinoma.  Collecting samples from cancer-draining veins provides improved diagnostic sensitivity, which could help identify patients at a higher risk or detect cancer progression earlier than peripheral blood tests.  Since CTC counts showed no direct association with clinical factors, continuous monitoring and larger-scale studies are essential to confirm their utility as predictive biomarkers, particularly in patients undergoing chemotherapy or those unsuitable for surgery.

🥳 This paper has been selected as the Journal Title Story in Cancers MDPI👏 📖 The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management ✍️ by Andrea Amaroli et al. Università degli Studi di Genova 🔗 Paper link here👉 https://lnkd.in/eUygKXwC

📜We share the #Review "Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions" ✍by SANDHYA DHIMAN et al. Karmanos Cancer Institute Wayne State University Find out more here👉 https://lnkd.in/d2UdrV9N

There is a lot of interest in using #shape and #textural analysis of three-dimensional data from medical scans (#radiomics) as a tool to enhance clinical decision making and, ultimately, improve patient care. Our recent work shows that radiomics features from Positron Emission Tomography with [18F] Fluorodeoxyglucose (#FDG #PET) coupled with machine learning models can improve the diagnostic accuracy of lymph-node status in patients with head and neck cancer. Francesco Bianconi, Roberto Salis, Mario Luca Fravolini, Usama Khan, Luca Filippi, Andrea Marongiu, Susanna Nuvoli, Angela Spanu, Barbara Palumbo Open access article available at https://lnkd.in/d7MJPfs7 Image source: Cancers MDPI (CC BY 4.0)

In Cancers MDPI we discuss a 🔑 topic “Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?” 🧬 🫁 ADCs bring targeted therapy to the next level by delivering cancer-killing agents directly to tumor cells, minimizing harm to healthy tissue. ➡️ But… drug-induced interstitial lung disease (D-ILD) remains a challenge. 🔑 Key insights from our paper: • 🎯 ADCs show potential in NSCLC treatment • 🌫️ D-ILD risk isn’t solely linked to target expression levels • Likely factors? Cytotoxic payloads & linker design 👉 What’s next? Safer ADC designs to reduce D-ILD risks while enhancing impact 🌐💥 #LungCancer #Oncology UAB O'Neal Comprehensive Cancer Center Vivek Subbiah, MD Sinchita Roy-Chowdhuri Ajay Sheshadri Sameer Deshmukh, MBBS Peters Solange

🧐Check out the #Article "Prognostic Factors in Patients Diagnosed with Gallbladder Cancer over a Period of 20 Years: A Cohort Study"  📌Access the full paper here: https://lnkd.in/dpee44-H 👏by Nima Toussi et al. University of Saskatchewan 🔆Main Findings: 🔹1. A significant proportion of patients with gallbladder cancer (GBC) were diagnosed at stage IV, and a considerable number of them were not referred to a cancer center. 🔹2. Out of the patients with stage I–III GBC, those with stage III disease and those residing in urban areas showed inferior disease-free survival outcomes compared to their counterparts. 🔹3. Across all GBC stages, an inferior overall survival was associated with several factors, including stage IV disease, the absence of surgery, the lack of referral to a cancer center, an older age (≥70 years), and a high neutrophil-to-lymphocyte ratio (>3.2). 🔆Implications of the Main Findings: 🔹1. The high proportion of late-stage diagnoses and low referral rates to cancer centers highlight the need for improved early-detection strategies and better referral practices to specialized cancer care to enhance patient outcomes. 🔹2. The association between urban residence and worse outcomes for early-stage GBC suggests that factors specific to urban environments may need further exploration. 🔹3. The factors associated with a poor overall survival, such as stage IV disease, lack of surgery, and high neutrophil-to-lymphocyte ratio, underscore the need for a comprehensive approach to management that includes timely surgery, referrals, and inflammatory marker monitoring to improve survival rates.

🥳 This paper has been selected as the Journal Title Story in Cancers MDPI👏 📖 Application of Nanoparticles for Magnetic Hyperthermia for Cancer Treatment—The Current State of Knowledge ✍️ by Dr. Marzena Szwed and Prof. Agnieszka Marczak, University of Lodz 🔗 Paper link here👉 https://lnkd.in/d-Y7jcJ2

📑Today we share the #Article "MCMC Methods for Parameter Estimation in ODE Systems for CAR-T Cell Cancer Therapy" 👥by Elia Antonini et al. 🔗Access the full paper here: https://lnkd.in/dkYmpw-u 🔆Main findings: 🔹1. We developed a mathematical framework using ordinary differential equations (ODEs) to describe CAR-T cell behavior in cancer patients. 🔹2. Bayesian parameter estimation techniques, including advanced algorithms such as Metropolis–Hastings and DEMetropolisZ, were employed to improve the model accuracy and understanding of CAR-T dynamics. 🔹3. The model was validated using real clinical data, accurately capturing key dynamics of CAR-T cell therapy, such as cell proliferation, memory retention, and exhaustion. 🔆Implications of the main findings: 🔹1. The framework enhances the understanding of CAR-T cell interactions, facilitating the prediction of therapy outcomes in clinical settings. 🔹2. Bayesian methods provide a robust approach for parameter estimation, offering the potential for more personalized and precise treatment strategies. 🔹3. The model’s predictive capabilities can contribute to optimizing CAR-T therapy, improving both its efficacy and safety by reducing adverse effects like cytokine release syndrome.